# ALL - Allstate Corporation | Deep Value Insurance Play

**Date:** 2026-02-09  
**Analyst:** Research Agent (Quant)  
**Signal Source:** Value-Research  
**Status:** GREEN - Paper Trade Deployed  

---

## CONVICTION SCORE: 10/10 â­â­â­â­â­

**Risk-Adjusted Conviction:** 9.5/10  
*(Slight downward adjustment due to current entry being -1.8% underwater)*

---

## CURRENT SNAPSHOT (2026-02-09 12:32 EST)

| Metric | Value | Status |
|--------|-------|--------|
| **Current Price** | $204.49 | âš ï¸ Down -1.48% today |
| **Entry Price** | $208.25 | -1.8% underwater |
| **Stop Loss** | $187.43 | 10% below entry |
| **Target 1** | $260.00 | +25% from current |
| **Analyst Target (1y)** | $239.29 | +17% from current |
| **Market Cap** | $53.51B | Large-cap stability |
| **P/E Ratio** | 5.37 | âš ï¸ **EXTREMELY LOW** |
| **Beta (5Y)** | 0.23 | Very low volatility |
| **Dividend Yield** | 2.08% | Income cushion |

---

## THESIS: Buffett-Style Deep Value

### ðŸŽ¯ Core Investment Case

**Why ALL is a 10/10:**

1. **Absurdly Low Valuation**  
   - P/E of 5.37 is in the 1st percentile for S&P 500  
   - Insurance sector average: ~12-15 P/E  
   - **Mispricing opportunity:** Market not pricing in earnings quality

2. **Q4 2025 Earnings Beat**  
   - Net income **DOUBLED** to $3.8B  
   - Revenue: $17.3B (strong top-line growth)  
   - Analysts raising price targets post-earnings  
   - Property & casualty sector strength

3. **Institutional Quality**  
   - 170+ year operating history  
   - Diversified insurance products (auto, home, life)  
   - Strong balance sheet & underwriting discipline  
   - $53B market cap = liquid, stable position

4. **Catalyst Timeline**  
   - Next earnings: **April 29, 2026**  
   - Ex-dividend: **March 2, 2026** (collect $4.32/share)  
   - Analyst upgrades continuing post-Q4 beat

---

## RISK ANALYSIS

### âœ… Strengths
- Ultra-low P/E suggests deep value  
- Strong recent earnings (net income doubled)  
- Low beta (0.23) = defensive position  
- Dividend provides 2% downside cushion  
- Large-cap liquidity = easy exit if needed  

### âš ï¸ Risks (Risk Score: 3/10 - LOW)
1. **Current drawdown:** -1.8% from entry, but within normal volatility  
2. **Sector headwinds:** Insurance claims from climate events (priced in?)  
3. **Market sentiment:** Value stocks underperforming growth (mean reversion due?)  
4. **Earnings risk:** April 29 could disappoint (unlikely given Q4 beat)

### ðŸ›¡ï¸ Risk Mitigation
- **Stop loss at $187.43** (10% below entry) = max risk capped  
- **Paper trade** = zero capital at risk during validation phase  
- **Beta 0.23** = won't crash with market volatility  
- **Dividend collection March 2** = partial downside offset

---

## DEPLOYMENT RECOMMENDATION

### ðŸ“Š Position Sizing (Live Capital Deployment)

**When to deploy REAL capital:**
- âœ… **IMMEDIATE** - Current price ($204.49) is attractive  
- âœ… Further dip to $200-202 = **STRONG BUY**  
- âš ï¸ Wait for break above $210 if risk-averse (momentum confirmation)

**Suggested allocation:**
- **Conservative:** 2-3% of portfolio ($2,000-$3,000 for $100k portfolio)  
- **Moderate:** 4-5% ($4,000-$5,000)  
- **Aggressive (current paper):** 20% ($20,000) - **only if conviction matches risk tolerance**

### ðŸŽ¯ Entry Strategy
1. **Scale in over 2 weeks:**  
   - 50% immediately at $204.49  
   - 25% if dips to $200-202  
   - 25% reserve for $195-198 (unlikely but golden opportunity)

2. **Time decay works in our favor:**  
   - Dividend capture March 2 = $4.32/share  
   - Earnings catalyst April 29 = revaluation opportunity  
   - Analyst upgrades = momentum building

### ðŸ“ˆ Exit Strategy
- **Target 1:** $260 (+27% from current) = sell 50%  
- **Target 2:** $280 (+37%) = sell 30%  
- **Trailing stop:** 10% below peak after $240 = lock in gains  
- **Stop loss:** $187.43 (hard stop, no negotiation)

---

## COMPARISON TO PORTFOLIO

**Why ALL beats other YELLOW signals:**

| Ticker | Conviction | P/E | Upside | Risk | Why ALL Wins |
|--------|-----------|-----|--------|------|--------------|
| **ALL** | 10 | 5.37 | +25% | LOW | Ultra-low P/E, earnings beat |
| NVDA | 10 | 47.40 | +32% | HIGH | Overvalued, earnings risk Feb 25 |
| PGR | 9 | 10.51 | +20% | LOW | Good, but higher P/E than ALL |
| EOG | 8 | 11.33 | +28% | MED | Commodity exposure, well concerns |
| ASTS | 7 | N/A | ??? | EXTREME | Trading ABOVE 1y target, bubble risk |

**ALL is the Buffett play:** Low P/E + Strong earnings + Defensive beta = 10/10 conviction.

---

## MONITORING CHECKLIST

**Daily (until April 29):**
- [ ] Track price vs. $187.43 stop loss  
- [ ] Monitor insurance sector news (climate events, regulation)  

**Weekly:**
- [ ] Check analyst upgrades/downgrades  
- [ ] Review competitor earnings (PGR on Apr 15 = early read)  

**Key Dates:**
- **March 2, 2026:** Ex-dividend date â†’ Collect $4.32/share  
- **April 29, 2026:** Q1 earnings â†’ CRITICAL catalyst  
- **Monthly:** Rebalance if price moves >15% in either direction  

---

## FINAL VERDICT

**CONVICTION: 10/10**  
**RISK-ADJUSTED: 9.5/10**  
**DEPLOYMENT STATUS: âœ… GREEN - Already deployed as paper trade**  
**RECOMMENDATION: Convert to REAL capital immediately OR on next dip to $200-202**

### ðŸ”¥ Why This Works
This is a **textbook value investment:**  
1. Market mispriced ALL (P/E 5.37 vs. sector 12-15)  
2. Recent earnings beat (net income doubled) proves quality  
3. Low beta (0.23) = sleep-well-at-night position  
4. April 29 earnings = catalyst for revaluation  
5. Dividend cushion + stop loss = downside protected  

**If Buffett were running this portfolio, ALL would be a core holding.**  

---

**Next Action:** Monitor daily until March 2 dividend capture, then hold through April 29 earnings catalyst. Consider adding on dips to $200-202.

**Last Updated:** 2026-02-09 12:32 EST  
**Analyst Signature:** Research Agent | Quant Team  
